You already have an account? Log In

When the brain attacks itself: understanding anti-NMDA receptor encephalitis

Posted on 03.06.2026

Imagine a person in their twenties or thirties — previously healthy, working, studying, raising kids — who within a few weeks becomes paranoid, agitated, hallucinating, and incoherent. The natural assumption, by family and even by clinicians, is that this is a sudden psychiatric breakdown: a first episode of psychosis, perhaps bipolar disorder, or a drug reaction. But for a small and easily missed group of patients, the cause isn't psychiatric at all. It's their own immune system attacking the brain.

That illness is anti-NMDA receptor encephalitis — an autoimmune disease only described in 2007, but increasingly recognised as one of the most common causes of non-infectious encephalitis in young adults. For Australians who have either received the diagnosis or are trying to make sense of a loved one's strange new symptoms, here is what the current medical literature tells us about how the disease behaves, how it's identified, and how it's treated.

An autoimmune disease that looks like a psychiatric one

Anti-NMDA receptor encephalitis is caused by antibodies the body produces against the NR1 subunit of the N-methyl-D-aspartate (NMDA) receptor — a key receptor in the brain involved in memory, learning, perception and behaviour. When those antibodies bind, the receptors are effectively switched off, and the brain begins to malfunction in ways that closely mimic severe mental illness.

The clinical picture is striking. Patients typically begin with what looks like an acute psychiatric crisis — paranoia, delusions, hallucinations, mood swings, insomnia, agitation — before deteriorating into seizures, abnormal movements (orofacial dyskinesias are classic), reduced consciousness and autonomic instability. A recent Cureus case series framed this neatly: autoimmune encephalitis frequently "masquerades as acute psychosis," and that masquerade is itself a major cause of treatment delay.

The human cost of that delay is real. As reported by CBC, one Canadian woman spent years being treated for bipolar disorder before clinicians realised her true diagnosis was an autoimmune disease — a story that is becoming uncomfortably common in the neurology literature.

Who gets it, and why

Anti-NMDA receptor encephalitis disproportionately affects young women, although children and men can also develop it. In a sizable minority of female patients the trigger is a tumour — most often an ovarian teratoma — that displays NMDA-receptor-like tissue, prompting the immune system to make antibodies that then cross-react with the brain. In others, the trigger is post-viral (notably after herpes simplex encephalitis), and in many cases, no clear cause is ever identified.

The disease can also coexist with, or unmask, other autoimmune conditions. A 2024 case report in Frontiers documented anti-NMDA receptor encephalitis that ultimately unmasked underlying Sjögren's disease — a reminder that the immune system rarely misbehaves in just one place, and that a diagnosis of autoimmune encephalitis often warrants a broader autoimmune work-up.

How it's diagnosed

The diagnostic pathway is methodical, and it has been refined enough that clinicians no longer need to wait weeks for antibody results before starting treatment. The Royal Australian College of General Practitioners (RACGP) has highlighted anti-NMDA receptor encephalitis as a condition GPs need to keep on their radar, particularly when a young patient presents with rapidly evolving psychiatric symptoms that don't fit the usual pattern.

Key diagnostic steps generally include:

Clinical assessment — looking for the characteristic combination of psychiatric features, seizures, movement disorders, autonomic dysfunction and reduced consciousness developing over days to weeks.
MRI of the brain — often normal or only subtly abnormal, which can be misleadingly reassuring.
EEG — frequently shows non-specific slowing, and occasionally a distinctive "extreme delta brush" pattern.
Lumbar puncture — cerebrospinal fluid typically shows mild inflammation (lymphocytic pleocytosis), and importantly is the most sensitive sample for detecting anti-NMDA receptor antibodies.
Antibody testing — confirming IgG antibodies against the NR1 subunit of the NMDA receptor in CSF is the gold standard.
Tumour screening — pelvic ultrasound, MRI or CT in women to look for an ovarian teratoma, as removing it is often curative.

One critical message from the literature: a normal MRI does not rule the disease out, and treatment should not be delayed waiting for antibody confirmation if the clinical picture is suggestive.

How it's treated

Treatment has two arms: removing the trigger and calming the immune response.

If a tumour is found, surgical removal is a priority — patients with teratomas tend to recover faster and more completely than those without. Immunotherapy is then layered on, typically in stages.

First-line therapy usually involves high-dose intravenous corticosteroids, intravenous immunoglobulin (IVIG), and/or plasma exchange (plasmapheresis). These work relatively quickly to reduce the circulating antibodies and dampen inflammation.

Second-line therapy — for patients who don't respond adequately — generally involves rituximab (which depletes the antibody-producing B cells) and/or cyclophosphamide. International cohort data show that patients escalated to second-line treatment when first-line fails do significantly better long-term than those who aren't.

Supportive care is just as important. Patients often need intensive care, anti-seizure medication, sedation for agitation, careful management of autonomic instability, and rehabilitation that may stretch over many months. The Cureus case report emphasises that early recognition and prompt immunotherapy are the single biggest predictors of a good outcome — and that delayed treatment, often because the illness was assumed to be psychiatric, leads to worse recovery.

Living with it: recovery, relapse and the long tail

The encouraging news is that the majority of patients recover substantially. With appropriate treatment, around 75–80% of people regain near-normal function, though recovery is slow — often measured in months to years rather than weeks. Cognitive issues (memory, concentration, executive function), fatigue, sleep disturbance, mood changes and headaches can linger long after the acute illness resolves.

Relapse occurs in roughly 12–25% of patients, sometimes years later, which is why ongoing neurology follow-up matters. Long-term immunosuppression is considered in patients who relapse or who didn't have a removable tumour.

For Australians navigating the system, this typically means a multidisciplinary team: a neurologist (ideally one with autoimmune neurology experience), psychiatry input for the behavioural symptoms, neuropsychology for cognitive rehabilitation, and a GP coordinating the whole picture. Patient advocacy groups — including the international Anti-NMDA Receptor Encephalitis Foundation — can be invaluable for connecting with others who've been through it.

Why awareness matters

Anti-NMDA receptor encephalitis is rare, but it is no longer obscure. It is now recognised as a leading cause of encephalitis in people under 30, and the diagnostic tools and treatments are well-established. The remaining barrier — as the recent literature keeps emphasising — is recognition. When a young person develops a rapidly evolving psychiatric illness with neurological features, this disease needs to be on the differential.

For anyone newly diagnosed, the early days can feel terrifying and disorienting, often with significant gaps in memory of the illness itself. But the trajectory is genuinely hopeful: this is a treatable autoimmune disease, not a life sentence of mental illness, and the medical understanding of it is improving year on year.